Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Marketing, Observational Study in Iran to Determine the Immunogenicity Status in Patients Who Have Received rFVIIa AryoSeven.

NCT03372993 is registered in ClinicalTrials.gov with AryoGen Pharmed Co. as lead sponsor.

NCT NCT03372993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03372993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Marketing, Observational Study in Iran to Determine the Immunogenicity Status in Patients Who Have Received rFVIIa AryoSeven.
Lead sponsor
AryoGen Pharmed Co.
Phase
Observational
Overall status
Completed
Start date
June 13, 2016
Completion date
April 15, 2021
Enrollment
200 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

factor vii deficiency, glanzmann's thrombasthenia, hemophilia a with inhibitor, hemophilia b with inhibitor